X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Torrent Pharma with Aventis Pharma - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

TORRENT PHARMA vs SANOFI INDIA - Comparison Results

TORRENT PHARMA    Change

Torrent Pharmaceuticals Ltd. is the flagship company of the Torrent Group set up in 1959. Based in Ahmedabad, it was promoted by Mr U.N. Mehta initially as Trinity Laboratories Ltd. and was later renamed to its current name. The company derives its r... More

SANOFI INDIA 
   Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    TORRENT PHARMA SANOFI INDIA TORRENT PHARMA/
SANOFI INDIA
 
P/E (TTM) x 25.1 30.0 83.7% View Chart
P/BV x 6.1 5.3 116.0% View Chart
Dividend Yield % 3.3 1.7 190.8%  

Financials

 TORRENT PHARMA   SANOFI INDIA
EQUITY SHARE DATA
    TORRENT PHARMA
Mar-16
SANOFI INDIA
Dec-16
TORRENT PHARMA/
SANOFI INDIA
5-Yr Chart
Click to enlarge
High Rs1,7204,560 37.7%   
Low Rs1,1344,400 25.8%   
Sales per share (Unadj.) Rs394.51,028.5 38.4%  
Earnings per share (Unadj.) Rs101.8129.0 78.9%  
Cash flow per share (Unadj.) Rs116.3186.0 62.5%  
Dividends per share (Unadj.) Rs40.0068.00 58.8%  
Dividend yield (eoy) %2.81.5 184.7%  
Book value per share (Unadj.) Rs200.3753.6 26.6%  
Shares outstanding (eoy) m169.2223.03 734.8%   
Bonus/Rights/Conversions ---  
Price / Sales ratio x3.64.4 83.0%   
Avg P/E ratio x14.034.7 40.4%  
P/CF ratio (eoy) x12.324.1 50.9%  
Price / Book Value ratio x7.15.9 119.8%  
Dividend payout %39.352.7 74.5%   
Avg Mkt Cap Rs m241,435103,174 234.0%   
No. of employees `00010.93.6 300.6%   
Total wages/salary Rs m8,5593,592 238.3%   
Avg. sales/employee Rs Th6,129.66,537.7 93.8%   
Avg. wages/employee Rs Th785.8991.4 79.3%   
Avg. net profit/employee Rs Th1,581.3819.8 192.9%   
INCOME DATA
Net Sales Rs m66,76423,686 281.9%  
Other income Rs m2,156708 304.6%   
Total revenues Rs m68,92024,394 282.5%   
Gross profit Rs m27,2045,281 515.1%  
Depreciation Rs m2,4611,313 187.4%   
Interest Rs m1,85915 12,391.3%   
Profit before tax Rs m25,0414,661 537.2%   
Minority Interest Rs m00-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m-1,4030-   
Tax Rs m6,4141,691 379.3%   
Profit after tax Rs m17,2242,970 579.9%  
Gross profit margin %40.722.3 182.8%  
Effective tax rate %25.636.3 70.6%   
Net profit margin %25.812.5 205.7%  
BALANCE SHEET DATA
Current assets Rs m46,62215,673 297.5%   
Current liabilities Rs m32,8436,678 491.8%   
Net working cap to sales %20.638.0 54.3%  
Current ratio x1.42.3 60.5%  
Inventory Days Days7476 97.7%  
Debtors Days Days7922 354.1%  
Net fixed assets Rs m39,0298,098 482.0%   
Share capital Rs m846230 367.4%   
"Free" reserves Rs m31,40017,088 183.8%   
Net worth Rs m33,89017,356 195.3%   
Long term debt Rs m18,6370-   
Total assets Rs m90,13625,400 354.9%  
Interest coverage x14.5311.7 4.6%   
Debt to equity ratio x0.50-  
Sales to assets ratio x0.70.9 79.4%   
Return on assets %21.211.8 180.1%  
Return on equity %50.817.1 297.0%  
Return on capital %48.526.9 180.2%  
Exports to sales %43.324.5 177.0%   
Imports to sales %6.928.0 24.5%   
Exports (fob) Rs m28,9345,801 498.8%   
Imports (cif) Rs m4,5846,627 69.2%   
Fx inflow Rs m29,1857,145 408.5%   
Fx outflow Rs m6,0216,846 87.9%   
Net fx Rs m23,165299 7,747.4%   
CASH FLOW
From Operations Rs m27,1323,226 841.1%  
From Investments Rs m-7,014-1,555 451.1%  
From Financial Activity Rs m-14,352-1,818 789.4%  
Net Cashflow Rs m5,767-147 -3,922.8%  

Share Holding

Indian Promoters % 71.5 0.0 -  
Foreign collaborators % 0.0 60.4 -  
Indian inst/Mut Fund % 7.0 14.4 48.8%  
FIIs % 12.6 14.6 86.3%  
ADR/GDR % 0.0 0.0 -  
Free float % 8.8 10.5 83.8%  
Shareholders   26,511 15,184 174.6%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare TORRENT PHARMA With:   UNICHEM LAB  AUROBINDO PHARMA  IPCA LABS  GLENMARK PHARMA  SUN PHARMA  

Compare TORRENT PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Sensex Trades Marginally Higher; Pharma Stocks Among Top Gainers(01:30 pm)

After opening the day in green, share markets in India witnessed choppy trades and are presently trading marginally above the dotted line.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

The Most Important Innovation in Finance Since Gold Coins(Vivek Kaul's Diary)

Aug 10, 2017

Bill connects the dots...between money and growth, real money and real resources, gold and cryptocurrencies...and between gold, cryptocurrencies, and time.

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

Bitcoin Continues Stellar Rise(Chart Of The Day)

Aug 10, 2017

Bitcoin hits an all-time high, is there more upside left?

5 Steps To Become Financially Independent(Outside View)

Aug 16, 2017

Ensure your financial Independence, and pledge to start the journey towards financial freedom today!

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

TORRENT PHARMA SHARE PRICE


Aug 22, 2017 01:40 PM

TRACK TORRENT PHARMA

  • Track your investment in TORRENT PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

MORE ON TORRENT PHARMA

TORRENT PHARMA 8-QTR ANALYSIS

COMPARE TORRENT PHARMA WITH

MARKET STATS